[Advances in targeted therapy for pulmonary arterial hypertension].

Pulmonary arterial hypertension (PAH) is a severe cardiovascular disorder characterized by progressive elevation in pulmonary vascular resistance and sustained increase in right ventricular afterload, which may lead to right heart failure and sudden death as the disease advances. This article focuses on PAH-targeted drug research, reviews the development of classical pathway agents, and elaborates on the molecular mechanisms and translational prospects of novel pathway therapeutics. Evidence indicates that continuous advancements in targeted pharmacotherapies for PAH have significantly improved clinical outcomes, offering new directions for the management of this condition.